Rikhia Chakraborty

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11121297/publications.pdf

Version: 2024-02-01

32 papers	1,363 citations	567281 15 h-index	580821 25 g-index
33 all docs	33 docs citations	33 times ranked	1800 citing authors

#	Article	IF	Citations
1	Cellular distribution of mutations and association with disease risk inÂLangerhans cell histiocytosis without BRAFV600E. Blood Advances, 2022, 6, 4901-4904.	5.2	4
2	Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood, 2021, 137, 1777-1791.	1.4	25
3	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nature Medicine, 2021, 27, 851-861.	30.7	38
4	IFN-Î³ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. Blood Advances, 2021, 5, 3457-3467.	5.2	23
5	MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a034892.	6.2	17
6	BRAFV600E vs cell of origin: what governs LCH?. Blood, 2021, 138, 1203-1204.	1.4	1
7	BRAFV 600E or mutant MAP2K1 human CD34+ cells establish Langerhans cellâ€“like histiocytosis in immune-deficient mice. Blood Advances, 2020, 4, 4912-4917.	5.2	6
8	Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma. Cancers, 2020, 12, 3603.	3.7	6
9	Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Blood Advances, 2020, 4, 87-99.	5.2	25
10	The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia. Blood, 2019, 134, 5196-5196.	1.4	2
11	Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH. Blood, 2019, 134, 3602-3602.	1.4	0
12	TCR Repertoire Clonality Analysis and Transcriptome Analyses of Immune Infiltrates in Patients with Langerhans Cell Histiocytosis Can Define Prognostic Biomarkers for Future Therapeutic Development. Blood, 2019, 134, 3601-3601.	1.4	0
13	Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort. Blood, 2019, 134, 2773-2773.	1.4	0
14	CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCHâ€associated neurodegeneration and mass lesions. Cancer, 2018, 124, 2607-2620.	4.1	73
15	RAF/MEK/extracellular signalâ€“related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. Journal of Experimental Medicine, 2018, 215, 319-336.	8.5	58
16	Inherited Genetic Risk Factors and Langerhans Cell Histiocytosis Relapse Events. Blood, 2018, 132, 4278-4278.	1.4	0
17	Whole Exome Analysis Reveals Key Genomic Differences between Sporadic and Endemic Pediatric Burkitt Lymphoma. Blood, 2018, 132, 4117-4117.	1.4	0
18	Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A populationâ€based caseâ€control study. Pediatric Blood and Cancer, 2017, 64, e26321.	1.5	7

#	Article	IF	Citations
19	p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clinical Cancer Research, 2017, 23, 6629-6639.	7.0	23
20	A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood, 2017, 130, 2229-2232.	1.4	15
21	New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Molecular Cancer, 2017, 16, 115.	19.2	37
22	Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget, 2017, 8, 46065-46070.	1.8	24
23	Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood, 2016, 128, 2533-2537.	1.4	122
24	Inflammatory Plasma Proteins Predict Disease Severity and Response to Therapy in Patients with LCH. Blood, 2015, 126, 4072-4072.	1.4	0
25	A Genome-Wide Assessment of Inherited Genetic Variants and the Risk of Langerhans Cell Histiocytosis. Blood, 2015, 126, 4059-4059.	1.4	0
26	BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. Journal of Experimental Medicine, 2014, 211, 669-683.	8.5	346
27	Differentiating Skin-Limited and Multisystem Langerhans CellÂHistiocytosis. Journal of Pediatrics, 2014, 165, 990-996.	1.8	77
28	Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood, 2014, 124, 3007-3015.	1.4	352
29	Mutually Exclusive Recurrent Somatic Mutations in MAP2K1 and BRAF Support a Central Role for ERK Activation in LCH Pathogenesis. Blood, 2014, 124, 5587-5587.	1.4	2
30	Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica, 2013, 98, 533-537.	3.5	30
31	Plasma Biomarker Profiling In Langerhans Cell Histiocytosis: Risk-Stratifying The Inflammatory Storm. Blood, 2013, 122, 2854-2854.	1.4	0
32	Changes in Chemokine Receptor Expression of Regulatory T Cells After Ex Vivo Culture. Journal of Immunotherapy, 2012, 35, 329-336.	2.4	9